QUECTEL-WIRELESS
Quectel Wireless Solutions, a global IoT solutions provider, announces that its industrial-grade 5G NR module RG500L-EU has gained GCF certification for operating on global 5G NR networks. The GCF certification means that the RG500L-EU module can help customers to efficiently deploy their 5G high-speed IoT devices worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109006142/en/
Quectel, a global IoT solutions provider, announces GCF certification for it's industrial-grade 5G NR module RG500L-EU (Photo: Business Wire)
Based upon the MediaTek T750 platform, the RG500L-EU integrates a 5G NR FR1 modem and a quadcore Arm Cortex-A55 processor. By leveraging the powerful CPU performance of the T750 chipset, customer devices can improve their device processing performance as well as enable significant cost optimization.
“The global certification by the GCF confirms our commitment to provide our customers with best-in-class IoT solutions, no matter where they are in the world,” said Dominikus Hierl, Senior Vice President Sales EMEA. “Quectel continues to drive IoT innovation, providing the very best in 5G modules and delivering the innovation our customers have come to expect in order to develop their 5G IoT applications.”
The module supports dual carrier aggregation (2CC CA) at 200MHz frequency band. This capability to combine available 5G spectrum assets can greatly improve signal coverage and transmission rates. Additionally, the RG500L-EU module can achieve a peak downlink rate of 4.67Gbps and a peak uplink rate of 1.25Gbps, bringing smooth and super-fast 5G speed experience to end users.
The RG500L-EU supports EasyMesh™ and WPA3 R3 encryption protocol, enabling IoT devices with more stable, cost-efficient and secure wireless connections. The module also offers flexible Wi-Fi configuration combinations, including single 5G 2x2 + 2.4G 2x2 dual-band, single 5G 4x4 + single 2.4G 4x4 dual-band, as well as single 5G 4x4 (5G high frequency band) + single 5G 4x4 (5G low frequency band) + single 2.4G 4x4 tri-band.
Featuring a compact design and low power consumption, the RG500L-EU can help customers to reduce time-consuming procedures including fixed network and equipment installation. Its rich peripheral interfaces including SGMII, PCIe and PCM give customers maximum flexibility in their IoT solution designs. In combination with Quectel’s unique QuecOpen platform, the RG500L-EU also improves customer terminal development efficiency and accelerates their time-to-market.
The RG500L-EU adopts an 8-antenna solution with four 2.7GHz antennas and four n77/n78 dedicated antennas to provide terminals with stronger and more stable signals as well as higher peak download rates. The module can additionally provide high gain antenna covering n78 band to help with signal reception.
In addition to the GCF certification, Quectel's 5G module RG500L-EU has also passed CE approval for the EU market as well as RCM approval for the Australian region. In the above areas, Quectel’s RG500L-EU module has already been chosen by customers to develop a variety of terminals including mobile hotspots, customer premise equipment (CPE), outdoor unit (ODU) and other 5G converged gateways and industrial gateways, which have been deployed in areas like industrial monitoring, remote collaboration, video conferencing, telemedicine, online education and many other fields.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109006142/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom